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Letters
COMMENT&RESPONSE
Notice of Duplicate Publication:
Heated, HumidifiedHigh-FlowNasal Cannula
vs Nasal Continuous Positive Airway Pressure
for Respiratory Distress Syndrome of Prematurity:
A Randomized Clinical Noninferiority Trial (JAMA
Pediatr. doi:10.1001/jamapediatrics.2016.1243)
We write to report that our publication in JAMA Pediatrics
(JAMA Pediatr . Publ ished online August 8, 2016.
doi:10.1001/jamapediatrics.2016.1243)1 included 177 study
participants (among 316 reported in the JAMA Pediatrics
article1) from an earlier study by our group that was pub-
lished in Pediatria Medica e Chirurgica (Pediatr Med Chir.
2014;36[4]:88. doi:10.4081/pmc.2014.88).2 However, that
study2 was not powered to assess the primary outcome that
we reported in JAMA Pediatrics. The primary outcome that is
appropriately powered in our article in JAMA Pediatrics is
the need for mechanical ventilation within 72 hours from
the beginning of the noninvasive respiratory support. We
regret that we did not report the partial duplication of study
participants in the JAMA Pediatrics article1 and that we did
not cite the previously published article. We apologize to the
readers and editors of JAMA Pediatrics for any confusion this
has caused.
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Modeling the Effects of Priming
With theWhole-Cell Bordetella
Pertussis Vaccine
To the EditorThemodeling study ofDeAngelis et al1 suggested
that substitution of 1 dose of whole-cell pertussis vaccine for
the first dose of acellular vaccine at age 6 to 8 weeks would
result in at least a 91% reduction in the incidence of pertussis.
As noted in the accompanying editorial, the validity of these
findings reliesonbothexplicit and implicit assumptionswithin
the model structure and its parameters. We go further to say
that suchaprofoundeffect onpertussis disease and transmis-
sion seems inherently unlikely and that implementation bar-
riers are understated.
The assumption driving the model is that acellular per-
tussis vaccineprotects against disease but has no effect on in-
fection and therefore transmission, whereas a single dose of
whole-cell vaccine has a strong effect on both disease and in-
fection. AlthoughWarfel et al2 showed that whole-cell vacci-
nated but not acellular vaccinated baboons are protected
against asymptomatic infection, thiswasnot in the context of
a single whole-cell vaccine dose. Secondary attack rates aris-
ing frompertussis cases amongpredominantlywhole-cell vac-
cinated children were reported from Senegal in the early
1990s.3 Infectiousnesswas significantly reduced (−83%; 95%
CI, 50%to93%) in childrenwith clinical pertussiswhohad re-
ceived 3 vaccine doses but not among 1-dose vaccinated chil-
dren (−47%; 95% CI, −128% to 23%). A further consideration
is marked variability in the effectiveness of whole-cell
vaccines,4 limiting generalizability of conclusions.
Pertussis vaccine boosting in pregnancy, now a standard
recommendation in many settings, has much greater poten-
tial for clinically significant blunting of antibody responses in
whole-cell vaccinated infants, among whom immune blunt-
ing from maternal antipertussis antibodies at comparatively
low levels has been demonstrated. On the other hand, con-
trary to fears about reactogenicityofwhole-cell vaccines, stud-
ies in the 1990s found this wasmodest after dose 1 and in ac-
celerated schedules.5
In summary, we caution that the range of values for rela-
tive effectiveness of acellular and whole-cell vaccines on in-
fectiousness in the DeAngelis et al study1 are implausible and
the model findings insufficient for serious policy consider-
ation. Reintroduction of awhole-cell vaccine as the first dose
in the infant schedule is a significant implementation chal-
lenge with highly uncertain benefits. Comparative immuno-
genicity and reactogenicity in prospective trials in humans in
the context ofmaternal immunization as standard of care are
needed.
Thomas Snelling, PhD, FRACP
Peter McIntyre, MBBS, PhD, FRACP, FAFPHM
1228 JAMAPediatrics December 2016 Volume 170, Number 12 (Reprinted) jamapediatrics.com
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/peds/935880/ by a Biblioteca IRCCS Ospedale Maggiore - Milano User  on 05/17/2017
